Day Two - Wednesday 4th December, 2024Wednesday, 4 December 2024 - GMT (Greenwich Mean Time, GMTZ)

Analyse CDMO partnership success factors. Evaluate outsourcing benefits versus in-house capabilities. Ensure scalability, consistency, and data security in CDMO collaborations. Provide access to GMP facilities for smaller companies.

Jazz Pharmaceuticals employ a risk based approach to new vendor onboarding – a technical deep dive to evaluate capabilities, identify risks and opportunities and establish mitigation / improvement plans, with a cross functional team across MS&T, QC / Analytical, Facilities and Utilities Eng and Process development.

Explore cloud MES benefits and challenges. Evaluate vendor offerings. Consider MES-specific cloud requirements. Anticipate future trends.

Enhance Ireland's CGT profile through effective marketing. Leverage Irish location for CGT advantages.

Developing a skilled workforce, expanding talent pools, and leveraging government support for education are crucial to meet biomanufacturing demands.

• Overview of Galapagos and our innovative decentralized T cell therapy manufacturing platform and clinical programs
• Key elements enabling scalable and consistent decentralized production at global scale
• Real world experience with a decentralized CAR-T manufacturing platform supporting Phase I/II clinical trials at the point-of-care in EU

• Panellists’ experiences and expertise in the space.
• Reimbursement & Market access considerations.
• How can we create links between academia, SMEs and pharma?
• Current funding landscape: VC, Angel, Grants, etc.
• Innovative funding mechanisms to balance risk and reward for investors and developers.
• Recovering from the Covid Bubble bursting
• Ensuring equitable access to advanced therapies across different economic landscapes.
• Impact of new EU Pharmaceutical Legislation – Intellectual Property Rights: How will this affect Biopharma?